Marisa Harney Biography and Net Worth

Marisa J. Harney serves as Executive Vice President, Chief Credit Officer of the Company. She has served as Executive Vice President and Chief Credit Officer since May 2018 and as Chief Credit Officer since December 2016. Prior to joining CIT, Ms. Harney served as Chief Risk Officer, GE Capital Americas, with oversight of all risk activities, and as an officer of GE from August 2013 until June 2016. She served as Head of Corporate Credit Risk of the Americas for Bank of America after performing in various roles of increasing responsibility in both the credit and risk departments. Before Bank of America, she served as Unit Head for Chemical Bank’s and CIBC World Markets’ Media & Telecom groups and as a Senior Credit Executive for Credit Suisse First Boston. Ms. Harney holds an MBA from the New York University Stern School of Business and a bachelor’s degree in finance from Fordham University.

What is Marisa Harney's net worth?: The estimated net worth of Marisa Harney is at least $54,088.50 as of August 19th, 2022. Ms. Harney owns 1,011 shares of CIT Group stock worth more than $54,089 as of April 26th. This net worth approximation does not reflect any other assets that Ms. Harney may own. Learn More about Marisa Harney's net worth.
How do I contact Marisa Harney?: The corporate mailing address for Ms. Harney and other CIT Group executives is 11 West 42nd Street, New York NY, 10036. CIT Group can also be reached via phone at (212) 461-5200 and via email at [email protected]. Learn More on Marisa Harney's contact information.
Has Marisa Harney been buying or selling shares of CIT Group?: Marisa Harney has not been actively trading shares of CIT Group during the past quarter. Most recently, Marisa Harney sold 7,670 shares of the business's stock in a transaction on Thursday, October 28th. The shares were sold at an average price of $49.45, for a transaction totalling $379,281.50. Learn More on Marisa Harney's trading history.
Who are CIT Group's active insiders?: CIT Group's insider roster includes Michael Brosnan (Director), John Fawcett (EVP), Marisa Harney (EVP), Wahida Plummer (EVP), Steve Solk (Insider), Edward Sperling (EVP), and Sheila Stamps (Director). Learn More on CIT Group's active insiders.

Marisa Harney Insider Trading History at CIT Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/28/2021	Sell	7,670	$49.45	$379,281.50

Marisa Harney Buying and Selling Activity at CIT Group

CIT Group Company Overview

CIT Group, Inc. is a financial holding company, which provides financing, leasing and advisory services. It operates through the following business segments: Commercial Banking, Consumer Banking and Corporate. The Commercial Banking segment consists of four divisions, commercial finance, rail, and real estate finance and business capital. It provides a range of lending, leasing and deposit products, as well as ancillary products and services, including factoring, cash management and advisory services, primarily to small and medium- sized companies, as well as to the rail industry. The Consumer Banking segment includes retail Banking, consumer lending, and SBA lending, which are grouped together for purposes of discussion as other consumer banking and legacy consumer mortgages. The Corporate segment consists of businesses and portfolios that they no longer consider strategic. These portfolios include equipment financing, secured lending and leasing and advisory services to small and middle-market businesses. The company was founded by Henry Ittelson in 1908 and is headquartered in New York, NY.

Today's Range

Now: $53.50

$51.36

$54.33

50 Day Range

MA: $51.72

$46.31

$53.61

2 Week Range

Now: $53.50

$34.77

$56.62

Volume

32,810,120 shs

Average Volume

778,897 shs

Market Capitalization

$5.31 billion

P/E Ratio

7.80

Dividend Yield

2.62%

Beta

1.48

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>